



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>C12P 17/18, A61K 31/43, C12N 1/20, C07D 503/00</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/18947</b> <b>(43) International Publication Date:</b> 6 April 2000 (06.04.00)
<b>(21) International Application Number:</b> PCT/EP99/07390 <b>(22) International Filing Date:</b> 23 September 1999 (23.09.99) <b>(30) Priority Data:</b> 98203314.4 29 September 1998 (29.09.98) EP <b>(71) Applicant (for all designated States except US):</b> DSM N.V. [NL/NL]; Het Overloon 1, NL-6411 TE Heerlen (NL). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> VISSER-LUIRINK, Gesina [NL/NL]; Frans Halsstraat 19 hs, NL-1072 BJ Amsterdam (NL). DE LAAT, Wilhelmus, Theodorus, Antonius, Maria [NL/NL]; Loopschansstraat 54, NL-4817 KW Breda (NL). KLOP, Jeroen, Martijn [NL/NL]; Aart van der Leeuwlaan 67, NL-2624 PL Delft (NL). <b>(74) Agent:</b> VISSER-LUIRINK, Gesina; DSM Patents & Trade-marks, Office Delft (994-0760), Wateringseweg 1, P.O. Box 1, NL-2600 MA Delft (NL).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> FERMENTATION OF CLAVULANIC ACID AT A CONTROLLED LEVEL OF AMMONIA <b>(57) Abstract</b> <p>A method for the production of clavulanic acid by the fermentation of a clavulanic acid producing microorganism at a controlled level of at least 50 mg/l ammonia has been provided for. Under the application of these reaction conditions surprisingly high production levels of clavulanic acid have been obtained.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## Fermentation of clavulanic acid at a controlled level of ammonia

I. 5

### Field of the invention

The present invention relates to the field of the fermentative production of clavulanic acid by fermentation of a clavulanic acid producing microorganism.

I. 10

### Background of the invention

*Streptomyces* are known to produce a large variety of secondary metabolites which can be applied in the manufacturing of pharmaceuticals. Examples of these pharmaceuticals belong to the classes produced by the *Streptomyces* and are for instance polyketides, macrolides, anthracyclines, tetracyclins, lipopeptides and  $\beta$ -lactams, see further Strohl (1997).

I. 20

One particular example is the production of the  $\beta$ -lactamase inhibitor clavulanic acid, a  $\beta$ -lactam compound which is produced by various microbial strains belonging to the genus of *Streptomyces* such as *S. clavuligerus* ATCC 27064, *S. jumonjinensis* (GB patent 1563103), *S. katsurahamanus* IFO 13716 FERM 3944 (JP patent 83009679B) and *Streptomyces* sp. P6621 FERM 2804 (JP patent application 55162993A).

I. 25

Secondary metabolism is regulated in various ways in *Streptomyces*. Such regulations may comprise the carbon catabolite, ammonium or phosphate repression or any other kind of metabolite that represses the synthesis of the secondary metabolite of interest. Carbon catabolites and ammonium repress the production of cephalosporins in *S. clavuligerus* (Aharonowitz and Demain 1978 and 1979), nitrogen catabolites regulate the production of spiramycin in *S. ambofaciens*

I. 30

(Untrau 1994), and phosphate, ammonium and glutamate repress the production of clavulanic acid in *S. clavuligerus* (Romero et al. 1984). The oxygen concentration influences the regulation of ammonium and phosphate on the antibiotic synthesis by *S. clavuligerus* (Fang & Demain, 1995). Various types of regulations involved in cephamycin production with various *Streptomyces* are described in Omstead et al (1985). High ammonium concentrations were found to repress streptonigrin biosynthesis in *S. flocculus* (Wallace et al. 1990). A similar negative influence of ammonia on the cephalosporin production by *Streptomyces clavuligerus* was already described by Aharonowitz and Demain (1979). Furthermore, as *S. clavuligerus* is urease positive, which urease is repressed by  $\text{NH}_4\text{Cl}$  (see page 2478 of Bascaran et al (1989)) and ureum has been produced during the clavulanic acid production (Elson, 1993), the production of clavulanic acid by *S. clavuligerus* is described to be especially high when the concentration of ammonium is kept low (WO 96/18743).

However, otherwise than described in the patent application WO 96/18743, surprisingly a large increase in the production of clavulanic acid with a *Streptomyces* was found when maintaining the ammonium concentration in an optimal rather high concentration range of about minimal 50 mg/l. When this ammonium concentration range was applied, the production of clavulanic acid was improved by more than 20%.

The application of an ammonium concentration of at least 50 mg/l to obtain a surprisingly high yield of clavulanic acid has never been described or suggested in the literature.

### Summary of the invention

A method has been provided for the production of clavulanic acid by the fermentation of a clavulanic acid producing microorganism on a suitable medium comprising carbon and nitrogen sources wherein during

I. 5 the fermentation of the clavulanic acid producing microorganism the concentration of ammonia is maintained equal to or higher than 50 mg/l, particularly equal to or higher than 75 mg/l, more particularly equal to or higher than 100 mg/l. The concentration of ammonium is regulated by  
I. 10 applying one or two of the measures selected from regulation of the rate of ammonium addition, for instance ammonium sulfate or urea or regulation of the addition of one or more ammonium containing titrants selected from ammonia and ammonium hydroxide, combined for instance with sulfuric acid and sodium hydroxide. Preferably the pH during this  
fermentation has been maintained between 6.5 and 7.5 and preferably the fermentation is carried out in a fed batch, continuous or semi-continuous mode.

I. 15 **Detailed description of the invention**

According to the present invention it was surprisingly found that when the ammonium concentration is maintained equal to or higher than 50 mg/l, particularly equal to or higher than 75 mg/l and more particularly  
I. 20 equal to or higher than 100 mg/l, the clavulanic acid production is largely improved compared to a fermentation process where the ammonium concentration is kept low (<50 mg/l). By using fed batch fermentation techniques known in the art, nutrients can be fed to an industrial fermentor in order to provide the optimal physiological conditions with the  
I. 25 aim to maximize output from a given fermentation process. As an example, the residual ammonium concentration in a fermentation broth can be controlled at the desired concentration range by adding an ammonium source continuously or discontinuously (intermittently) to the fermentor. This can be done either directly by manipulating the flow of  
I. 30 the nitrogen source (ammonium, ammonium salts like ammonium chloride, ammonium nitrate, ammonium phosphate and ammonium carbonate or urea as an ammonium precursor), or indirectly by adding ammonium as an

alkaline titrant, eventually alternating with sodium hydroxide in order to prevent excess ammonium dosage. Furthermore, the ammonium concentration can be reduced for instance by manipulation of the temperature or pH, which leads to an increased growth rate and an increased ammonium consumption rate. The ammonium concentration can be controlled by adjusting the flow of the nitrogen source or by manipulation of the alkaline titrant and/or the pH.

According to the present invention the ammonium concentration is maintained equal to or higher than 50 mg/l. On the other hand, the ammonium concentration must be low enough for reducing the repression of secondary metabolism and avoiding toxicity of ammonium. For instance, the ammonium concentration could be maintained below 2500 mg/l, preferably 1000 mg/l, for instance 500 mg/l.

The microorganism used for production of clavulanic acid may be any *Streptomyces*, optionally improved for growth and/or clavulanic acid production by means of classical strain improvement or by recombinant DNA techniques, for instance *S. clavuligerus* or *S. jumonjinensis*.

The production of clavulanic acid is carried out by fermentation of a *Streptomyces* on a suitable medium comprising various carbon and energy sources like sugars such as glucose, fructose, sucrose, maltose, lactose, or polysaccharides like starch, maltodextrins and inuline or other fructose polymers, proteins such as flours from nuts, vegetables, seeds, cereals, grasses such as those useful in fermentation industry; soybean flour, linseed flour, peanut flour, potato flour, sunflower, pea- or beanflour, cotton seed flour, wheat gluten, whole wheat, rice meal, or proteins derived from animal sources called peptones, or proteins derived from microbial sources like yeast extracts, triglycerides such as soybean oil, sunflower oil, olive oil, tri-oleate etc., (poly-) alcohols such as ethanol, propanol, glycerol, mannitol, or organic acids or a salt thereof such as acetate, propionate, succinate, adipate, malonate, fumarate, citrate, lactate, gluconate etc. and nitrogen sources such as ammonium salts,

I. 5 ammonium, urea, nitrate, asparagine, aspartate, glutamate, lysine and from complex sources such as protein products derived from microbial source (yeast extract) or plants (corn steep liquor, soybean flour, cotton seed flour etc.) and animals (peptones). Phosphor is either supplied in the form of an inorganic salt, or as a phosphor protein like casein, or bound to inositol in the form of phytate as present in many plant protein sources like soybean flour or bound in nucleotides as present in yeast extracts.

I. 10 Further vitamins and various sorts of inorganic anions such as sulphates, phosphates, chlorides, borates, molybdate, iodate and inorganic cations such as potassium, sodium, zinc, manganese, magnesium, iron, copper, cobalt, nickel may be added to the fermentation medium.

I. 15 A fermentation is started by inoculating from a preculture or inoculum fermentation at a volume of 1 to 50% of the main fermentation medium, particularly from 5 to 20%. The process may last from 24 to 400 hours and especially from 48 to 168 hours. The temperature will be kept between 20 and 40 °C, in particular between 25 and 35 °C, and even more particular between 25 and 30 °C. The pH should be maintained preferably at pH 6 to 8, more preferably between pH 6.5 and I. 20 7.5 by means of titration with an alkaline substance such as ammonia, sodium hydroxide, potassium hydroxide, calcium hydroxide, or an organic base like lysine, arginine and histidine or a combination of these alkaline substances and an acid substance, such as the inorganic acids like sulphuric acid, hydrochloric acid, phosphoric acid and nitric acid. I. 25 Alternatively, an organic acid may be used such as glutamate, citrate, gluconate or acetate.

I. 30 The dissolved oxygen concentration is preferably controlled in the optimal range for the process by varying one or more of the following parameters: the oxygen concentration in the inlet gas, application of overpressure, modification of stirrer speed or airflow. The range may vary between 0 and 100% of air saturation.

Carbon dioxide should be kept at non-toxic concentrations by increasing the airflow through the fermentor so that the carbon dioxide concentration in the outlet-gas is less than 5%, more particular less than 2.5%.

I. 5           The fermentation can be carried out in a batch, a fed batch, or a continuous fermentation process mode.

I. 10           The process may be carried out by controlling various non-growth limiting nutrients in their optimal concentrations. Dependent on the growth limiting nutrient of choice, these growth-non-limiting nutrients may contain any relevant source of carbon, nitrogen, phosphor or sulphur or may contain oxygen.

I. 15           Of course, the recovery of the impure clavulanic acid solution as formed by the fermentative process of the present invention as well as the subsequent conversion thereof into a pharmaceutically acceptable salt by methods known in the art do form an aspect of the present invention. One of the most advantageous procedures is the conversion of the impure clavulanic acid into an amino salt thereof by adding the corresponding amino salt forming compound as for instance N,N,N',N'-tetramethylethylenediamine, 1,3-bis(di-methylamino)-2-propanol, t-butylamine, t-octylamine, benzhydrylamine and bis (2-(dimethyl-amino)ethyl)ether and reacting said amine clavulanate with a non-toxic pharmaceutially acceptable salt as for instance potassium ethylhexanoate to form the corresponding purified salt, for instance potassium clavulanate.

I. 25           The following examples are only to be considered as illustration of the present invention.

I. 30

#### References



Strohl W.R., Biotechnology of Industrial Antibiotics, Marcel Dekker Inc., page 1-48 (1997).

- I. 5 Aharonowitz Y. and Demain A.L., Antimicrobial Agents and Chemotherapy Vol. 14, No. 2, pages 159-164 (1978).

Aharonowitz Y. and Demain A.L., Can. J. Microbiol. 25, 61-67 (1979).

- I. 10 Aharonowitz Y. and Friedrich C.G., Arch. Microbiol. 125, 137-142 (1980).

Elson S.W., Baggaley K.H., Davidson M., Fulston M., Nickolson N.H., Risbridger, G.D. and Tyler, J.W., J. Chem. Soc., Chem. Commun. 1213 (1993).

- I. 15 Butterworth, Biotechnology of Industrial Antibiotics, Marcel Dekker Inc., pages 225-235 (1984).

- I. 20 Romero J. Liras P. and Martin J.F., Appl. Microbiol. Biotechnol. 20, 318-325 (1984).

Omstead D.R., Hunt G.R. and Buckland B.C. in Comprehensive Biotechnology Pergamon Press, Vol. 3, Edited by Harvey W. Blanch, Stephen Drew and Daniel I.C. Wang, pages 187-210 (1985).

- I. 25 Brana A.F., Paiva N. and Demain A.L., J. of Gen. Microbiol. 132, 1305-1317 (1986).

- I. 30 Brana A.F., Wolfe S. and Demain A.L., Arch. Microbiol. 146, 46-51 (1986).

Bascaran V., Hardisson C. and Brana A.F., J. of General Microbiology 135, 2465-2474 (1989).

I. 5 Bascaran V., Hardisson C. and Brana A.F., J. of General Microbiology 135, 2475-2482 (1989).

Wallace K.K., Payne G.F. and Speedie M.K., J. of Industrial Microbiology, 6, 43-48 (1990).

I. 10 Untrau S., Lebrihi A., Lefebvre G. and Germain P., Curr. Microbiol. 28 (1994).

Kasarenini S. and Demain A.L., J. of Industrial Microbiology 13, 217-219 (1994).

I. 15 Fang A. and Demain A.L., J. of Industrial Microbiology 15, 407-410 (1995).

I. 20 **Example 1**

*Streptomyces clavuligerus* ATCC27064 was improved for clavulanic acid production by means of several rounds of classic mutation (UV, nitroso guanidine (NTG)) and selection in shake flask cultures  
I. 25 whereby clavulanic acid production was tested by imidazole methods as known in the art. The strain was conserved as vegetative mycelium grown for 48 hours in Tryptone Soytone Broth-medium (TSB-medium) at 28 °C in a shaker incubator shaken at 280 rpm and stored frozen at -80 °C.

I. 30 1 ml of the frozen mycelium was inoculated to 100 ml of a sterilized (30 minutes, 121 °C) preculture medium containing 5-20 g/l maltose.1aq, 15-30 g/l bacto tryptone, 15-30 g/l bacto peptone, 1-10 g/l

bacto soytone, mono potassium phosphate (1-5 g/l) and 0.2 g/l synthetic antifoam.

I. 5 After 72 hours of cultivation at 27 °C, 100 ml of the culture is transferred to the inoculum fermentor with 70 l of steam-sterilized medium at pH 7 containing glycerol (20-50 g/l), soybean flour (20-40 g/l), casein hydrolysate (10-50 g/l), mono potassium phosphate (2-5 g/l), a suitable trace element cocktail and synthetic antifoam (1 g/l). The inoculum fermentation medium was again grown for 72 hours at 26-30 °C keeping the dissolved oxygen concentration above 25% of air  
I. 10 saturation by increasing airflow, agitation and backpressure if required.

The main fermentation is inoculated by transferring 9 l of the inoculum broth to the main fermentor by pressurizing the inoculum fermentor containing 150 l medium sterilized by steam prior to inoculation. The medium contained glycerol (50-100 g/l), soybean flour (5-  
I. 15 20 g/l), casein hydrolysate (10-50 g/l), mono potassium phosphate (0.5-2 g/l), a suitable trace element cocktail and synthetic antifoam (0.2 - 2 g/l).

The pH was maintained at 7 +/- 0.25 by titration with NaOH and sulphuric acid while the temperature was kept between 26 and 29 °C by pumping cooling water through the jackets of the fermentor. The  
I. 20 dissolved oxygen concentration was kept above 25% of air saturation by increasing airflow, backpressure and stirrer speed if required.

In case of ammonium controlled fermentations, 0.58 g/l of ammonium sulphate was added to the main fermentation medium after sterilisation and ammonium was fed to the fermentor using a sterile  
I. 25 diluted solution of the same containing 12 g/l NH<sub>3</sub> as sulphate salt. The flow was adjusted to get the ammonium at the desired concentration range upon off-line measurement of the concentration of ammonium every 2 hours. When the concentration of ammonium in the broth got higher than 500 mg/l, the pH was increased by addition of an alkaline titrant  
I. 30 with 0.2 unit in order to reduce the ammonium concentration under that level.

I. 5 In table 1 we see that when the ammonium concentration was controlled above 50 mg/l, the clavulanic acid production was increased with more than 25% in two independent runs. During the reference fermentation experiment ammonium has been below 50 mg/l for 35 hours; between 5 and 40 hours after inoculation. After this period ammonium rises due to clavulanic acid production.

Table 1. Experimental results of clavulanic acid-fermentations on a 300 l scale with and without ammonium control.

I. 10

Experiment	Relative Titer
Reference example without ammonium control	100%
Ammonium controlled example 1	132%
Ammonium controlled example 2	127%

**CLAIMS**

- I. 5           1.       A method for the production of clavulanic acid by the fermentation of a clavulanic acid producing microorganism on a suitable medium comprising carbon and nitrogen sources wherein during the fermentation of the clavulanic acid producing microorganism the concentration of ammonium is maintained about equal to or higher than 50 mg/l.
- I. 10           2.       A method according to claim 1, wherein the concentration of ammonium is maintained about equal to or higher 75 mg/l.
- I. 15           3.       A method according to claim 2, wherein the concentration of ammonium is maintained about equal to or higher than on 100 mg/l.
- I. 20           4.       A method according to anyone of the claims 1, 2 or 3, wherein the concentration of ammonium is regulated by applying one or two of the measures selected from regulation of the rate of ammonium addition or regulation of the addition of one or more titrants.
- I. 25           5.       A method according to claim 4, wherein the concentration of ammonium is regulated by the addition of ammonium sulfate or urea.
- I. 30           6.       A method according to claim 4, wherein the concentration of ammonium is regulated by the addition of one or more titrants selected from ammonia and ammonium hydroxide, combined with sulfuric acid and optionally sodium hydroxide.
- I. 30           7.       A method according to anyone of the claims 1 - 6, characterized by maintaining the pH between 6.5 and 7.5.

8. A method according to anyone of the claims 1 - 7 wherein the fermentation is carried out in a fed batch, continuous or semi-continuous mode.

I. 5 9. A method for the purification of clavulanic acid wherein impure clavulanic acid from the fermentation broth produced according to anyone of the claims 1 - 8 is isolated and purified subsequently.

I. 10 10. A method according to claim 9, and subsequent conversion to a non-toxic pharmaceutically acceptable salt thereof by converting the impure clavulanic acid into an amine salt thereof by adding the corresponding amine salt forming compound and reacting said amine clavulanate with a non-toxic pharmaceutically acceptable salt to form the corresponding purified salt of clavulanic acid.

I. 15

# INTERNATIONAL SEARCH REPORT

Inter.      nal Application No  
PCT/EP 99/07390

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7    C12P17/18    A61K31/43    C12N1/20    C07D503/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7    C12P    A61K    C12N    C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 39137 A (LEK PHARMACEUTICAL & CHEMICAL ;BROWNE ROBIN FORSYTHE (GB); KRANJC) 23 October 1997 (1997-10-23)	1-5,7-9
Y	abstract; claims 11-13,15,16; example 2 page 1, paragraph 5 -page 2, paragraph 1 page 3, paragraph 5 -page 4, paragraph 5 ---	10
Y	EP 0 026 044 A (BEECHAM GROUP PLC) 1 April 1981 (1981-04-01) abstract; claims 1-3; examples 1-4 ---	10
A	WO 96 18743 A (SMITHKLINE BEECHAM PLC ;VALENTINE BRIAN PETER (GB); JEFFKINS PAUL) 20 June 1996 (1996-06-20) cited in the application --- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

13 January 2000

Date of mailing of the international search report

20/01/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Oderwald, H

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/07390

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>BASCARAN V ET AL: "Isolation and characterization of nitrogen-deregulated mutants of Streptomyces clavuligerus" JOURNAL OF GENERAL MICROBIOLOGY, vol. 135, no. 9, September 1989 (1989-09), pages 2475-2482, XP002086396 cited in the application abstract</p> <p>-----</p>	



# INTERNATIONAL SEARCH REPORT

information on patent family members

Inter national Application No

PCT/EP 99/07390

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9739137	A	23-10-1997	SI 9600120 A	31-12-1997
			AU 2516497 A	07-11-1997
			CA 2251596 A	23-10-1997
			EP 0906446 A	07-04-1999
			PL 329291 A	15-03-1999
			ZA 9703139 A	05-08-1998
<hr/>				
EP 0026044	A	01-04-1981	AT 3716 T	15-06-1983
			AU 535198 B	08-03-1984
			AU 6163280 A	09-04-1981
			CA 1157862 A	29-11-1983
			DK 70884 A,B,	15-02-1984
			DK 363080 A,B,	25-02-1981
			ES 494431 A	16-07-1981
			FI 802590 A,B,	25-02-1981
			GR 69870 A	20-07-1982
			HK 1086 A	10-01-1986
			IE 50047 B	05-02-1986
			IL 60885 A	30-11-1983
			JP 1610847 C	15-07-1991
			JP 2034954 B	07-08-1990
			JP 56034685 A	06-04-1981
			JP 1730079 C	29-01-1993
			JP 2167286 A	27-06-1990
			JP 4015234 B	17-03-1992
			KE 3577 A	10-01-1986
			KR 8600343 B	12-04-1986
			MY 99985 A	31-12-1985
			NO 802498 A,B,	25-02-1981
			NZ 194703 A	02-09-1983
			PL 226397 A	22-05-1981
			US 4454069 A	12-06-1984
			US 4647659 A	03-03-1987
			ZA 8005206 A	26-08-1981
<hr/>				
WO 9618743	A	20-06-1996	AU 702660 B	25-02-1999
			AU 4343296 A	03-07-1996
			BR 9509878 A	25-11-1997
			CA 2207411 A	20-06-1996
			CN 1169162 A	31-12-1997
			CZ 9701771 A	17-09-1997
			EP 0796340 A	24-09-1997
			FI 972446 A	09-06-1997
			HU 77082 A	02-03-1998
			JP 10510426 T	13-10-1998
			NO 972647 A	09-06-1997
			NZ 298035 A	28-01-1999
			PL 320662 A	13-10-1997
			US 5985624 A	16-11-1999
<hr/>				